Zymeworks (ZYME) and Akebia Therapeutics (AKBA) Head-To-Head Analysis

Zymeworks (NYSE: ZYME) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Earnings and Valuation

This table compares Zymeworks and Akebia Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zymeworks $11.00 million 23.53 -$33.80 million ($2.27) -4.49
Akebia Therapeutics $1.53 million 449.84 -$135.74 million ($3.16) -4.61

Zymeworks has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.2% of Zymeworks shares are owned by institutional investors. Comparatively, 62.2% of Akebia Therapeutics shares are owned by institutional investors. 8.7% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zymeworks and Akebia Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zymeworks -1,387.89% -117.85% -54.48%
Akebia Therapeutics -137.80% -198.85% -41.16%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Zymeworks and Akebia Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks 2 0 4 0 2.33
Akebia Therapeutics 0 1 7 0 2.88

Zymeworks currently has a consensus target price of $16.00, indicating a potential upside of 56.86%. Akebia Therapeutics has a consensus target price of $23.50, indicating a potential upside of 61.40%. Given Akebia Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Zymeworks.

Summary

Akebia Therapeutics beats Zymeworks on 8 of the 13 factors compared between the two stocks.

About Zymeworks

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company’s lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company’s vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply